ENTITY
Actinogen Medical

Actinogen Medical (ACW AU)

17
Analysis
Health CareAustralia
Actinogen Medical Limited operates as a biotechnology company. The Company focuses on the treatment of alzheimer's disease and mild cognitive impairment. Actinogen Medical develops a novel drug to treat the condition and other age-related neurodegenerative diseases.
more
Refresh
01 Mar 2024 07:10Issuer-paid

Actinogen Medical - Pressing forward with Xanamem

Having shown cognitive activity in prior trials, Actinogen began its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive...

Share
23 Dec 2023 01:10Issuer-paid

Actinogen Medical - Phase IIb XanaMIA study opens first study site

Actinogen Medical has opened the first investigational study site for its Phase IIb XanaMIA trial of lead candidate Xanamem in patients with...

Share
26 Oct 2023 01:10Issuer-paid

Actinogen Medical - Taking steps to mitigate funding headwinds

Actinogen is refining the design of its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive impairment (CI) associated...

Share
10 Aug 2023 19:10Issuer-paid

Actinogen Medical - Funding the next stage of Xanamem development

Actinogen recently provided a Q423 quarterly update summarising that its two development programmes for lead candidate Xanamem remain on track,...

Share
08 Jun 2023 22:16Issuer-paid

Actinogen Medical - Refining the upcoming XanaMIA Phase IIb study

Actinogen intends to start patient enrolment and dosing in H2 CY23 in the Phase IIb XanaMIA study portion assessing Xanamem in lead indication...

Share
x